106 related articles for article (PubMed ID: 28394918)
21. Repositioning of the antipsychotic trifluoperazine: Synthesis, biological evaluation and in silico study of trifluoperazine analogs as anti-glioblastoma agents.
Kang S; Lee JM; Jeon B; Elkamhawy A; Paik S; Hong J; Oh SJ; Paek SH; Lee CJ; Hassan AHE; Kang SS; Roh EJ
Eur J Med Chem; 2018 May; 151():186-198. PubMed ID: 29614416
[TBL] [Abstract][Full Text] [Related]
22. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
23. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
24. Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
Chang CH; Liu WT; Hung HC; Gean CY; Tsai HM; Su CL; Gean PW
BMC Cancer; 2017 Dec; 17(1):905. PubMed ID: 29284440
[TBL] [Abstract][Full Text] [Related]
25. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model.
Benedetti E; Antonosante A; d'Angelo M; Cristiano L; Galzio R; Destouches D; Florio TM; Dhez AC; Astarita C; Cinque B; Fidoamore A; Rosati F; Cifone MG; Ippoliti R; Giordano A; Courty J; Cimini A
Oncotarget; 2015 Dec; 6(39):42091-104. PubMed ID: 26540346
[TBL] [Abstract][Full Text] [Related]
26. Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Watanabe T; Ohtani T; Aihara M; Ishiuchi S
J Neurosurg; 2013 Apr; 118(4):838-45. PubMed ID: 23311938
[TBL] [Abstract][Full Text] [Related]
27. The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
Awde AR; Boisgard R; Thézé B; Dubois A; Zheng J; Dollé F; Jacobs AH; Tavitian B; Winkeler A
J Nucl Med; 2013 Dec; 54(12):2125-31. PubMed ID: 24212976
[TBL] [Abstract][Full Text] [Related]
28. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
29. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
[TBL] [Abstract][Full Text] [Related]
30. Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.
Stec WJ; Rosiak K; Siejka P; Peciak J; Popeda M; Banaszczyk M; Pawlowska R; Treda C; Hulas-Bigoszewska K; Piaskowski S; Stoczynska-Fidelus E; Rieske P
Oncotarget; 2016 May; 7(22):31907-25. PubMed ID: 27004406
[TBL] [Abstract][Full Text] [Related]
31. Enhanced expression of proapoptotic and autophagic proteins involved in the cell death of glioblastoma induced by synthetic glycans.
Faried A; Arifin MZ; Ishiuchi S; Kuwano H; Yazawa S
J Neurosurg; 2014 Jun; 120(6):1298-308. PubMed ID: 24678780
[TBL] [Abstract][Full Text] [Related]
32. Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.
Kurokawa C; Geekiyanage H; Allen C; Iankov I; Schroeder M; Carlson B; Bakken K; Sarkaria J; Ecsedy JA; D'Assoro A; Friday B; Galanis E
J Neurooncol; 2017 Jan; 131(1):41-48. PubMed ID: 27816996
[TBL] [Abstract][Full Text] [Related]
33. Quantitative in vivo bioluminescence imaging of orthotopic patient-derived glioblastoma xenografts.
Koessinger AL; Koessinger D; Stevenson K; Cloix C; Mitchell L; Nixon C; Gomez-Roman N; Chalmers AJ; Norman JC; Tait SWG
Sci Rep; 2020 Sep; 10(1):15361. PubMed ID: 32958777
[TBL] [Abstract][Full Text] [Related]
34. Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM; Sánchez-Gómez P; Vaz Salgado MÁ; Gargini R; Balañá C
Expert Opin Investig Drugs; 2018 Oct; 27(10):823-829. PubMed ID: 30247945
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.
Marrero L; Wyczechowska D; Musto AE; Wilk A; Vashistha H; Zapata A; Walker C; Velasco-Gonzalez C; Parsons C; Wieland S; Levitt D; Reiss K; Prakash O
Neoplasia; 2014 Oct; 16(10):874-82. PubMed ID: 25379024
[TBL] [Abstract][Full Text] [Related]
36. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
37. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
40. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
